Drug intelligence / Profile preview

ANV200

Development stage: Unknown
Lead developer: Anaveon
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

ANV200 is a proprietary monoclonal antibody developed by Anaveon. It binds to a specific epitope of the programmed cell death protein 1 (PD-1) receptor, but unlike conventional anti-PD-1 antibodies, it does not block the binding or signaling of PD-L1. This unique binding profile suggests that ANV200 may modulate immune responses differently from standard PD-1 inhibitors, potentially offering novel therapeutic benefits in immuno-oncology or other immune-mediated conditions[9].

Targets

IL21R (Interleukin-21 receptor)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on ANV200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANV200.

Explore the full profile